PDCD1 and non-small cell lung carcinoma: Furthermore, meta-analyses of multiple immunotherapy trials compared to standard chemotherapy demonstrated that only EGFR-wild-type patients benefit from anti-PD-1 or anti-PD-L1 antibodies, while patients with EGFR-mutated tumors did not achieve improved overall survival or longer progression-free survival in patients with advanced non-small cell lung carcinoma (NSCLC) while on ICI therapy [44].